Williams VS, Smith MY, Fehnel SE. The validity and utility of bpi interference measures addressing the impact of pain. Poster presented at the Annual International Society for Quality of Life Research (ISOQOL) Conference; November 2003.
Allen RM, Granger AL, Dykstra LA. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov 1;307(2):785-92.
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.
Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. Safety profile of smell and taste disorders in patients treated with cox-2 specific inhibitors and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.